Eltrombopag has the efficacy of elevating platelets and can be used to treat primary immune thrombocytopenic purpura and other diseases. 1. Eltrombopag is a thrombopoietin receptor agonist drug, primary immune thrombocytopenic purpura patients in the presence of thrombocytopenia, at the same time the use of splenectomy or other drugs are not effective, can be used Eltrombopag. 2. Adverse reactions: Eltrombopag can cause common adverse reactions, including nausea and vomiting, muscle pain, sensory abnormalities, dyspepsia, cataracts and so on. 3. Contraindication: It must be contraindicated in case of hypersensitivity to any of the ingredients contained in Eltrombopag. Precautions: Eltrombopag needs to be administered on an empty stomach. If liver function test abnormalities or platelet count overreaction occurs during the medication period, the patient needs to interrupt the treatment according to the doctor’s instructions. Eltrombopag should be used in strict accordance with the doctor’s instructions, after the use of abnormalities should be promptly notified to the specialized physician.